CD19 and multiple sclerosis: Inebilizumab also targets antibody-producing CD-19-positive plasmablasts and plasma cells while Obexelimab not only targets CD19 but binds simultaneously to both CD19 and FcγRIIb promoting internalization of CD19 in the lipid rafts, markedly enhancing the inhibitory FcγRIIB and downregulating CD19 as proposed for the IgG4-neurological autoimmunities [102–104]; 2) bortezomib that targets plasmblasts; and 3) Zanubrutinib and Rilzabrutinib, both Bruton’s tyrosine kinase inhibitors, showing already promise in patients with multiple sclerosis [103].